Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo Jin Kim, Zhi Zhang Yang, Anne J. Novak, Stephen M. Ansell

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although immune checkpoint molecules regulate the progression of certain cancers, their significance in malignant development of Waldenstrom macroglobulinemia (WM), an incurable low-grade B-cell lymphoma, remains unknown. Recently, cytokines in the bone marrow (BM) microenvironment are shown to contribute to the pathobiology of WM. Here, we investigated the impact of cytokines, including interleukin-6 (IL-6) and IL-21, on immune regulation and particularly on the programmed death-1 (PD-1) and its ligands PD-L1 and PD-L2. We showed that IL-21, interferon g, and IL-6 significantly induced PD-L1 and PD-L2 gene expression in WM cell lines. Increased PD-L1 and PD-L2 messenger RNA was also detected in patients’ BM cells. Patients’ nonmalignant BM cells, including T cells and monocytes, showed increased PD-L1, but minimal or undetectable PD-L2 surface expression. There was also very modest PD-L1 and PD-L2 surface expression by malignant WM cells, suggesting that ligands are cleaved from the cell surface. Levels of soluble ligands were higher in patients’ BM plasma and blood serum than controls. Furthermore, IL-21 and IL-6 increased secreted PD-L1 in the culture media of WM cell lines, implying that elevated levels of soluble PD-1 ligands are cytokine mediated. Soluble PD-1 ligands reduced T-cell proliferation, phosphorylated extracellular signal-regulated kinase and cyclin A levels, mitochondrial adenosine triphosphate production, and spare respiratory capacity. In conclusion, we identify that soluble PD-1 ligands are elevated in WM patients and, in addition to surface-bound ligands in WM BM, could regulate T-cell function. Given the capability of secreted forms to be bioactive at distant sites, soluble PD-1 ligands have the potential to promote disease progression in WM.

Original languageEnglish (US)
Pages (from-to)1985-1997
Number of pages13
JournalBlood Advances
Volume2
Issue number15
DOIs
StatePublished - Aug 14 2018

Fingerprint

Waldenstrom Macroglobulinemia
Ligands
T-Lymphocytes
Interleukin-6
Bone Marrow
Cytokines
Bone Marrow Cells
Cyclin A
Cell Line
Extracellular Signal-Regulated MAP Kinases
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Interferons
Culture Media
Disease Progression
Monocytes
Adenosine Triphosphate
Cell Proliferation
Gene Expression
Messenger RNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. / Jalali, Shahrzad; Price-Troska, Tammy; Paludo, Jonas; Villasboas, Jose; Kim, Hyo Jin; Yang, Zhi Zhang; Novak, Anne J.; Ansell, Stephen M.

In: Blood Advances, Vol. 2, No. 15, 14.08.2018, p. 1985-1997.

Research output: Contribution to journalArticle

Jalali, Shahrzad ; Price-Troska, Tammy ; Paludo, Jonas ; Villasboas, Jose ; Kim, Hyo Jin ; Yang, Zhi Zhang ; Novak, Anne J. ; Ansell, Stephen M. / Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. In: Blood Advances. 2018 ; Vol. 2, No. 15. pp. 1985-1997.
@article{48c01a09da3e414cab11b2b2f69c4c15,
title = "Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia",
abstract = "Although immune checkpoint molecules regulate the progression of certain cancers, their significance in malignant development of Waldenstrom macroglobulinemia (WM), an incurable low-grade B-cell lymphoma, remains unknown. Recently, cytokines in the bone marrow (BM) microenvironment are shown to contribute to the pathobiology of WM. Here, we investigated the impact of cytokines, including interleukin-6 (IL-6) and IL-21, on immune regulation and particularly on the programmed death-1 (PD-1) and its ligands PD-L1 and PD-L2. We showed that IL-21, interferon g, and IL-6 significantly induced PD-L1 and PD-L2 gene expression in WM cell lines. Increased PD-L1 and PD-L2 messenger RNA was also detected in patients’ BM cells. Patients’ nonmalignant BM cells, including T cells and monocytes, showed increased PD-L1, but minimal or undetectable PD-L2 surface expression. There was also very modest PD-L1 and PD-L2 surface expression by malignant WM cells, suggesting that ligands are cleaved from the cell surface. Levels of soluble ligands were higher in patients’ BM plasma and blood serum than controls. Furthermore, IL-21 and IL-6 increased secreted PD-L1 in the culture media of WM cell lines, implying that elevated levels of soluble PD-1 ligands are cytokine mediated. Soluble PD-1 ligands reduced T-cell proliferation, phosphorylated extracellular signal-regulated kinase and cyclin A levels, mitochondrial adenosine triphosphate production, and spare respiratory capacity. In conclusion, we identify that soluble PD-1 ligands are elevated in WM patients and, in addition to surface-bound ligands in WM BM, could regulate T-cell function. Given the capability of secreted forms to be bioactive at distant sites, soluble PD-1 ligands have the potential to promote disease progression in WM.",
author = "Shahrzad Jalali and Tammy Price-Troska and Jonas Paludo and Jose Villasboas and Kim, {Hyo Jin} and Yang, {Zhi Zhang} and Novak, {Anne J.} and Ansell, {Stephen M.}",
year = "2018",
month = "8",
day = "14",
doi = "10.1182/bloodadvances.2018021113",
language = "English (US)",
volume = "2",
pages = "1985--1997",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia

AU - Jalali, Shahrzad

AU - Price-Troska, Tammy

AU - Paludo, Jonas

AU - Villasboas, Jose

AU - Kim, Hyo Jin

AU - Yang, Zhi Zhang

AU - Novak, Anne J.

AU - Ansell, Stephen M.

PY - 2018/8/14

Y1 - 2018/8/14

N2 - Although immune checkpoint molecules regulate the progression of certain cancers, their significance in malignant development of Waldenstrom macroglobulinemia (WM), an incurable low-grade B-cell lymphoma, remains unknown. Recently, cytokines in the bone marrow (BM) microenvironment are shown to contribute to the pathobiology of WM. Here, we investigated the impact of cytokines, including interleukin-6 (IL-6) and IL-21, on immune regulation and particularly on the programmed death-1 (PD-1) and its ligands PD-L1 and PD-L2. We showed that IL-21, interferon g, and IL-6 significantly induced PD-L1 and PD-L2 gene expression in WM cell lines. Increased PD-L1 and PD-L2 messenger RNA was also detected in patients’ BM cells. Patients’ nonmalignant BM cells, including T cells and monocytes, showed increased PD-L1, but minimal or undetectable PD-L2 surface expression. There was also very modest PD-L1 and PD-L2 surface expression by malignant WM cells, suggesting that ligands are cleaved from the cell surface. Levels of soluble ligands were higher in patients’ BM plasma and blood serum than controls. Furthermore, IL-21 and IL-6 increased secreted PD-L1 in the culture media of WM cell lines, implying that elevated levels of soluble PD-1 ligands are cytokine mediated. Soluble PD-1 ligands reduced T-cell proliferation, phosphorylated extracellular signal-regulated kinase and cyclin A levels, mitochondrial adenosine triphosphate production, and spare respiratory capacity. In conclusion, we identify that soluble PD-1 ligands are elevated in WM patients and, in addition to surface-bound ligands in WM BM, could regulate T-cell function. Given the capability of secreted forms to be bioactive at distant sites, soluble PD-1 ligands have the potential to promote disease progression in WM.

AB - Although immune checkpoint molecules regulate the progression of certain cancers, their significance in malignant development of Waldenstrom macroglobulinemia (WM), an incurable low-grade B-cell lymphoma, remains unknown. Recently, cytokines in the bone marrow (BM) microenvironment are shown to contribute to the pathobiology of WM. Here, we investigated the impact of cytokines, including interleukin-6 (IL-6) and IL-21, on immune regulation and particularly on the programmed death-1 (PD-1) and its ligands PD-L1 and PD-L2. We showed that IL-21, interferon g, and IL-6 significantly induced PD-L1 and PD-L2 gene expression in WM cell lines. Increased PD-L1 and PD-L2 messenger RNA was also detected in patients’ BM cells. Patients’ nonmalignant BM cells, including T cells and monocytes, showed increased PD-L1, but minimal or undetectable PD-L2 surface expression. There was also very modest PD-L1 and PD-L2 surface expression by malignant WM cells, suggesting that ligands are cleaved from the cell surface. Levels of soluble ligands were higher in patients’ BM plasma and blood serum than controls. Furthermore, IL-21 and IL-6 increased secreted PD-L1 in the culture media of WM cell lines, implying that elevated levels of soluble PD-1 ligands are cytokine mediated. Soluble PD-1 ligands reduced T-cell proliferation, phosphorylated extracellular signal-regulated kinase and cyclin A levels, mitochondrial adenosine triphosphate production, and spare respiratory capacity. In conclusion, we identify that soluble PD-1 ligands are elevated in WM patients and, in addition to surface-bound ligands in WM BM, could regulate T-cell function. Given the capability of secreted forms to be bioactive at distant sites, soluble PD-1 ligands have the potential to promote disease progression in WM.

UR - http://www.scopus.com/inward/record.url?scp=85059078853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059078853&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018021113

DO - 10.1182/bloodadvances.2018021113

M3 - Article

C2 - 30104397

AN - SCOPUS:85059078853

VL - 2

SP - 1985

EP - 1997

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 15

ER -